ClinicalTrials.gg
CompletedNCT00234923MONARKUpdated Apr 3, 2008

Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients

A Phase 3 interventional study of lopinavir/ritonavir and lamivudine/zidovudine in HIV Infection, sponsored by Abbott. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-03.

Sponsored by Abbott · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
67th of 126
138 · median 154
Started
2003
with 2 others
Phase 3
50 of 132
2 open now
Registered
74th of 132
by date
Lead sponsor
4 of 132
Abbott

Among the 132 studies testing lamivudine in HIV Infections, this one is the 67th largest by enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2003, is one of 50 in phase 3, and was the 74th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this pilot study is to obtain a preliminary assessment of the antiviral activity and tolerability of Kaletra single agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm

03

Conditions studied

  • HIV Infection

Browse trials for

Keywords

  • HIV Infection
  • Kaletra
  • Lopinavir
  • Ritonavir
  • Treatment Naive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Antiretroviral naïve
  • RNA \<100,000 copies/mL
  • >100 cells/mL at screening
  • with Score > 70
  • If female,

    • non-pregnant and
    • not breastfeeding
  • No AIDS opportunistic infection within 30 days of screening

Exclusion criteria

Exclusion Criteria:

  • Subject with an primo-infection status
  • Recent history of drug and/or alcohol abuse
  • History of psychiatric illness
  • If presence of the following mutations :

    • in the protease : one among 32,47,48,50,82,84,90
    • OR more than 3 mutations from the other points of the LPV mutation score:10,20,24,46,53,54,63,71
    • in the reverse transcriptase : 215 or 184.
  • If abnormal laboratory results such as :

    • \<8 g/dl
    • \<750 cells/µl
    • count\<50 000/ml
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
138 participants (actual)

Study arms

  • Active comparator
    1

    Kaletra Monotherapy: lopinavir/ritonavir

    Drug: lopinavir/ritonavir

  • Active comparator
    2

    Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine

    Drug: lopinavir/ritonavir · Drug: lamivudine/zidovudine

Interventions

  • Druglopinavir/ritonavir

    400 mg lopinavir/ 100 mg ritonavir, BID

    Also known as: ABT-378, Kaletra

  • Druglamivudine/zidovudine

    Drug pages: Lamivudine · Zidovudine

    300mg lamivudine/150mg zidovudine, BID

06

What researchers measure

Primary outcomes

  1. Antiviral efficacy by HIV RNA

    Time frame: 48 Weeks

Secondary outcomes

  1. Arm comparisons: CD4 evolution, occurrence of HIV protease and RT mutation, occurrence of AIDS clinical events, safety of NRTI-sparing vs. a PI with 2 NRTIs regimen: clinical and biological tolerance, patient's adherence and quality of life.

    Time frame: 48 weeks

  2. To assess in the LPV/r single-drug regimen arm: virological control, CD4 evolution, safety

    Time frame: 96 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tran TA, Ghosn J, Avettand-Fenoel V, Hendel-Chavez H, de Goer de Herve MG, Cohen-Codar I, Rouzioux C, Delfraissy JF, Taoufik Y. Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy. J Antimicrob Chemother. 2015 Sep;70(9):2627-31. doi: 10.1093/jac/dkv138. Epub 2015 May 28. PubMed 26023212 ↗
  • Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group. Long-term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x. Epub 2009 Aug 13. PubMed 19682100 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003 and a primary completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Oct 10, 2005
Start
Aug 2003
Primary completionActual
Feb 2007
Last update
Apr 3, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00234923
Lead sponsor
Abbott
First posted
Oct 10, 2005
Start date
Aug 2003
Primary completion
Feb 2007
Last update
Apr 3, 2008

Study contacts

Global Medical Information
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Zidovudine

Start the discussion